Engagement highlights
CRA has conducted numerous vaccines projects this year. Here, we highlight some of the most impactful engagements from our strategy and policy work in 2024.
Strategy
Country resource to broaden NITAG recommendations for adult vaccines
The client wanted to develop a resource to help country team members identify strategies and tactics to support broadening recommendations for adult vaccines for diseases such as influenza and COVID-19. The CRA team developed a workshop-in-box resource that countries could use to define an action plan to overcome country-specific challenges.
Global payer and policy implications of preventative multi-mAb launches
Many companies launch preventative mABs for immunocompromised patients, resulting in preventative multi-mAb use in the same high-risk patients. The project identified who these patients are and how payer and policy makers react to the vaccination and budget challenges at hand.
Global payer and policy insights on willingness to pay and grant access to multi-anti-viral vaccines
The client was interested in assessing the willingness to pay and grant access to a novel combination of an established anti-viral with a vaccine against viral infection where currently there is no vaccine available. Insights supported the clinical and commercial development strategy.
Early global commercial attractiveness assessment of a mAb for prevention of C-Diff infections
The client wanted to understand the value of developing a mAb for primary and recurrent prevention of C-Diff infections. Special focus was put on the population-price trade-off from the payer and policy perspective and on what constitutes high-risk patients for primary vs recurrent prevention. Insights changed the clinical and commercial development program.
Payer value proposition and objection handling in re-launch of an innovative flu vaccine
The team supported the global payer and NITAG interactions during (re)launch of an innovative flu vaccine targeting children.
Policy
The impact of vaccine purchasing programs on broader market dynamics
In the US, the client wanted to build evidence of the broader impacts and unintended consequences of state Universal Purchase (UP) Programs for vaccines to establish them as a thought leader in this space.
Policy issues affecting the availability, affordability, and access (AAA) of vaccines in Europe
Evidence was collected on the root cause of each of the three A’s for the inclusion of vaccines in national immunisation programmes across Europe and how policy solutions could address these issues across the vaccine market access (VMA) pathway.
Thought leadership
The Vaccines Lab presented two posters at ISPOR Europe 2024
- Top trends affecting the vaccines market and their implications on access policy and public health decision-making
- Value recognition of combination vaccines: What is needed to support access and uptake?
